Home » Topics » Hematologic, BioWorld Science

Hematologic, BioWorld Science
RSS

Novel forward-oriented therapeutic vector for hemoglobin disorders

Dec. 21, 2016

Phase I and phase II extension study results for fitusiran

Dec. 21, 2016

ProMetic Life Sciences begins rolling submission of BLA for plasminogen

Dec. 21, 2016

Kiadis obtains U.K. approvals for phase I/II trial of ATIR-201 for thalassemia

Dec. 15, 2016

Omeros provides continued access to OMS-721 for patient with HSCT-TMA

Dec. 7, 2016

Calimmune and Cincinnati Children's Hospital Medical Center to work together on gene therapies

Dec. 7, 2016

Phase III study of Shire's Vonvendi meets primary endpoint

Dec. 5, 2016

Global Blood Therapeutics' GBT-440 granted orphan designation in E.U.

Dec. 1, 2016

Idelvion launched in Japan

Nov. 30, 2016

GlaxoSmithKline begins phase III program for daprodustat in anemia associated with CKD

Nov. 25, 2016

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 18, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 16, 2026
Gene replacement rescues autism-related phenotypes in mice
BioWorld Science
Autism spectrum disorder (ASD), developmental epileptic encephalopathies and other neurodevelopmental disorders are driven by the disruption of genes regulating...
For clonal hematopoiesis, epigenetics can be in driver’s seat
BioWorld Science
Clonal hematopoiesis (CH), where few blood stem cells produce a significant fraction of mature blood cells that are genetically identical, is partly an inevitable...
Elixiron’s enrupatinib shows upbeat interim phase II AD results
BioWorld
Elixiron Immunotherapeutics Inc. announced positive interim open-label phase II Alzheimer’s disease (AD) study findings of enrupatinib, an oral brain-penetrant...